Zhongnan Medical Journal Press

Home Results

A total of 7 result was found. Results that relate to Cost-effectiveness analysis

Cost-effectiveness analysis of abemaciclib plus fulvestrant in the second-line treatment for HR﹢/HER2﹣ advanced breast cancer

Published on Chinese Journal of Pharmacoepidemiology 2023,32(11):1259-1266.
6899 times 1897 times

Xi ZHAO Xi YAN Ning LI Chun-Xia HOU

Abemaciclib Fulvestrant Hormone receptor-positive breast cancer Markov model Cost-effectiveness analysis
Details
Cost-effectiveness analysis of enzalutamide in the treatment of metastatic prostate cancer

Published on Chinese Journal of Pharmacoepidemiology 2024,33(3):269-276.
8915 times 2193 times

YANG Lei WANG Fengling HUANG Ling LI Yan ZHENG Hanrui ZHENG Lingli CHEN Li

Enzalutamide Metastatic prostate cancer Markov model Cost-effectiveness analysis
Details
Research progress of equity-informative health economic evaluation

Published on Chinese Journal of Pharmacoepidemiology 2024,33(8):929-937.
13072 times 2317 times

FANG Nan HE Xiaoning WU Jing

Economic evaluation Equity Equity-based weighting Distributional cost-effectiveness Extended cost-effectiveness analysis
Details
Economic evaluation of multi-station drug dispensing robots for intravenous infusion preparation

Published on Chinese Journal of Pharmacoepidemiology 2024,33(12):1375-1381.
16879 times 1527 times

SUN Zhihong ZHAO Shaoliang ZHOU Furong LIU Feiyu WANG Pengcheng ZOU Shaohua GUO Chenyu

Multi-station dispensing robot Pharmacy intravenous admixture services Dispensing efficiency Cost-effectiveness analysis Economic evaluation
Details
Pharmacoeconomic evaluation of ribociclib plus fulvestrant in second-line treatment of HR+/HER2- advanced breast cancer for postmenopausal women

Published on Chinese Journal of Pharmacoepidemiology 2025,34(6):612-620.
8660 times 1352 times

JIA Caifeng WANG Jie ZHANG Sen WANG Meiqi LI Sainan WANG Mingxia

Ribociclib Fulvestrant Advanced breast cancer Postmenopausal Pharmacoeconomic evaluation Cost-effectiveness analysis
Details
Evaluation of the pharmacoeconomics of recombinant human thrombopoietin for the treatment of cancer therapy-induced thrombocytopenia

Published on Chinese Journal of Pharmacoepidemiology New Online
534 times 181 times

LIANG Hai XIA Runan CHEN Huijuan JIANG Mengyu LI Fanqin YANG Miao MA Jinghe

Recombinant human thrombopoietin Interleukin-11 Cancer Thrombocytopenia Decision tree Cost-effectiveness analysis
Details
Cost-effectiveness analysis of fondaparinux compared with low molecular-weight heparin in the treatment of recurrent spontaneous abortion

Published on Chinese Journal of Pharmacoepidemiology 2026,35(3):281-287.
590 times 185 times

ZHU Yurong LI Lanlan ZHANG Rui DAI Wei YANG Weihu

Recurrent spontaneous abortion Fondaparinux Low molecular-weight heparin Cost-effectiveness analysis
Details